Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 4/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23905574 | 0.91 | MKNK1 (0.37) | DRD1FGFR2MKNK1FGFR1TGFBR1 | |
| SCHEMBL23906136 | 0.86 | MIF (0.36) | DRD1MAPK1 | |
| SCHEMBL23884399 | 0.83 | RXRA (0.43) | MAPK1 | |
| SCHEMBL30252031 | 0.83 | RXRA (0.43) | MAPK1 | |
| SCHEMBL25475040 | 0.81 | NPC1 (0.39) | DRD1MKNK1 | |
| SCHEMBL23905576 | 0.79 | CHEK2 (0.37) | FGFR2MKNK1MAPK1 | |
| SCHEMBL23884493 | 0.79 | STK17A (0.43) | FGFR2MKNK1FGFR1MAPK1 | |
| SCHEMBL30251987 | 0.79 | STK17A (0.43) | FGFR2MKNK1FGFR1MAPK1 | |
| SCHEMBL23884547 | 0.78 | MKNK1 (0.37) | FGFR2MKNK1FGFR1TGFBR1TRPA1 | |
| SCHEMBL23905579 | 0.77 | FGFR2 (0.35) | FGFR2MKNK1FGFR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | DRD1 577/4885FGFR2 4885/4885MKNK1 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.